Harmony Biosciences Holdings, Inc. (HRMY) News
Follow Harmony Biosciences Holdings, Inc. (HRMY) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 15 public stories across 9 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Undervalued healthcare stocks with attractive valuation grades
Healthcare stocks continue to attract investor attention as managed care providers, pharmaceutical companies, biotechnology firms and healthcare services businesses navigate changing demand and industry conditions.With v
NEWS | Sep 15, 2026, 05:21 PM UTC
L
Harmony Biosciences CMO Budur Kumar sold shares worth $1.4M
Budur Kumar, Harmony Biosciences’ Chief Medical Officer, reported common stock sales under a Rule 10b5-1 trading plan. The reported weighted-average selling prices ranged from $41.9839 to $43.1014 per share.
EQUITY | Sep 09, 2026, 09:21 PM UTC
L
Ten healthcare stocks with A-rated valuations and strong revenue growth
Healthcare stocks remain a focal point for investors as pharmaceutical innovation, biotechnology advancements, and managed care expansion continue to drive growth across the sector.While many healthcare companies trade a
EQUITY | Sep 09, 2026, 03:01 PM UTC
L
Harmony Biosciences to present EPX-100 encore data at European Epilepsy Congress
Harmony Biosciences Holdings plans to present encore data from its EPX-100 (clemizole hydrochloride) investigation at the 16th European Epilepsy Congress, Sept. 5-9 in At…
GEOPOLITICS | Sep 03, 2026, 12:07 PM UTC
H
HRMY - Harmony Biosciences Announces Poster Presentations at the 16th European Epilepsy Congress
HRMY - Harmony Biosciences Announces Poster Presentations at the 16th European Epilepsy Congress
GEOPOLITICS | Sep 03, 2026, 12:05 PM UTC
L
Harmony Biosciences to Participate in 2026 Cantor Healthcare Conference
Harmony Biosciences will participate in the 2026 Cantor Global Healthcare Conference.
EQUITY | Aug 27, 2026, 12:07 PM UTC
L
HRMY - Harmony Biosciences to Participate in 2026 Cantor Global Healthcare Conference
HRMY - Harmony Biosciences to Participate in 2026 Cantor Global Healthcare Conference
EQUITY | Aug 27, 2026, 12:05 PM UTC
L
Harmony Biosciences Says New Data Supports Neurology Pipeline
Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY ) shares closed higher by around 8% on Tuesday following the company's announcement of record revenue for the second quarter of 2026. The neurological disease-focused phar
EARNINGS | Aug 05, 2026, 10:56 AM UTC
L
Harmony Biosciences Hldgs Affirms FY2026 Sales Guidance of $1.000B-$1.040B vs $1.020B Est
Harmony Biosciences Hldgs (NASDAQ: HRMY ) affirms FY2026 sales outlook from $1.000 billion-$1.040 billion to $1.000 billion-$1.040 billion vs $1.020 billion estimate.
EARNINGS | Aug 04, 2026, 11:30 AM UTC
H
Harmony Biosciences Reports Record Q2 Revenue
Harmony Biosciences posts record Q2 revenue
EQUITY | Aug 04, 2026, 11:30 AM UTC
H
HRMY Preliminary Q226 revenues exceed expectations and 2026 guidance positions WAKIX for clear blockbuster status— market reaction is overdo
HRMY Preliminary Q226 revenues exceed expectations and 2026 guidance positions WAKIX for clear blockbuster status— market reaction is overdone and creates a buying opportunity, in HCW's view @ HCW
EARNINGS | Jul 17, 2026, 12:54 PM UTC
H
Harmony Biosciences Reports Preliminary Q2 WAKIX Sales Of ~$261M, Up 30% YoY; Appoints Stephen Mollichella As Interim CFO
Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY ) today announced preliminary, unaudited second quarter 2026 net product revenue for WAKIX® (pitolisant) of approximately $261 million, representing a new quarterly revenu
EARNINGS | Jul 16, 2026, 12:40 PM UTC
H
Harmony Biosciences Hldgs Affirms Prelim FY2026 Sales Guidance of $1.000B-$1.040B vs $1.014B Est
Harmony Biosciences Hldgs (NASDAQ: HRMY ) affirms prelim FY2026 sales outlook from $1.000 billion-$1.040 billion to $1.000 billion-$1.040 billion vs $1.014 billion estimate.
EARNINGS | Jul 16, 2026, 12:38 PM UTC
H
HRMY - Harmony Biosciences preannounces record quarterly revenue for Q2 2026, reaffirms full-year 2026 revenue guidance, and announces CFO t
HRMY - Harmony Biosciences preannounces record quarterly revenue for Q2 2026, reaffirms full-year 2026 revenue guidance, and announces CFO transition Harmony Biosciences - reiterates fy2026 net product revenue guidance o
EARNINGS | Jul 16, 2026, 12:30 PM UTC
L
Deutsche Bank Maintains Hold on Harmony Biosciences Hldgs, Raises Price Target to $36
Deutsche Bank analyst David Hoang maintains Harmony Biosciences Hldgs (NASDAQ: HRMY ) with a Hold and raises the price target from $30 to $36.
EQUITY | Jun 30, 2026, 05:14 PM UTC